CAMBRIDGE, Mass., November 20, 2023 /PRNewswire/ — QurAlis Companya clinical-stage biotechnology company delivering scientific breakthroughs in powerful precision medicines that will change the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today : Kasper RoetPh.D., CEO and Founder, to Present at Piper Sandler 35th Annual Healthcare Conference underway November 28-30, 2023 In New York, New York.
Dr. Roet will provide an overview of the company and an update on Thursday November 30, 2023 has 2:30 p.m. ET.
QurAlis’ corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.
About QurAlis Corporation
At QurAlis, we are neuro-pioneers in search of healing. We work with a relentless pursuit of knowledge, keen attention to craftsmanship, and an optimistic mindset to discover and develop effective precision medicines that will change the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative diseases. Founded by an internationally renowned team of neurodegenerative biologists from Harvard Medical School And Harvard University, QurAlis is developing a pipeline of therapeutic candidates that target specific components of ALS and FTD pathology and patient populations defined based on both disease-causing genetic mutations and clinical biomarkers. For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.
SOURCE QurAlis
